Workflow
无锡药明康德新药开发股份有限公司 2024年年度股东大会、2025年第一次A股类别股东会议及2025年第一次H股类别股东会议决议公告

Core Viewpoint - The company held its 2024 annual general meeting and approved several key resolutions, including a share buyback plan and financial reports for the year [2][11]. Group 1: Meeting Details - The annual general meeting was held on April 29, 2025, at the Sheraton Hotel in Shanghai [2]. - All 12 current directors and 3 supervisors attended the meeting, along with the company secretary and CFO [3]. Group 2: Resolutions Passed - The following resolutions were approved: - 2024 Board of Directors' Work Report [4]. - 2024 Supervisory Board's Work Report [4]. - 2024 Financial Settlement Report [5]. - 2024 Profit Distribution Plan [5]. - Authorization for the Board to formulate a mid-term dividend plan [5]. - Special dividend plan for 2025 [5]. - External guarantee limit for 2025 [5]. - Reappointment of accounting firms for 2025 [5]. - Approval for foreign exchange hedging business limit for 2025 [5]. - Change of registered capital and amendments to the Articles of Association [6]. - Share buyback plan for A-shares [6][12]. - Approval of the 2025 H-share incentive trust plan [7]. - General authorization for the Board to issue debt financing instruments [8]. Group 3: Share Buyback Plan - The company plans to repurchase A-shares with a total fund of RMB 1 billion, estimating to buy back approximately 10,863,661 shares, which is about 0.38% of the total issued shares [12]. - The registered capital will decrease from RMB 2,887,992,582 to RMB 2,877,128,921 following the buyback [12]. Group 4: Debt Notification - The company notified creditors that they have 45 days from the announcement date to declare their debts and request repayment or guarantees [13]. - Specific documentation is required for debt declaration, including contracts and identification [14][15].